- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | Central Library of Charles University
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Reduced Thrombin Generation and Soluble P-selectin After Intravenous Enoxaparin During PCI2011 | First Faculty of Medicine
- Influence of Long-Term Thromboprophylaxis With Low-Molecular-Weight Heparin (Enoxaparin) on Changes of Bone Metabolism Markers in Pregnant Women2011 | First Faculty of Medicine
- Changes in coagulation after single i. v. bolus 0, 75 mg per kg of the low molecular weight heparin enoxaparin during PCI - a pharmacokinetic study2006 | First Faculty of Medicine
- FXa Inhibition and Coagulation Changes During DVT Prophylaxis by Enoxaparin Over the Course of a 15-Day Follow-Up in Septic Patients2010 | First Faculty of Medicine
- Enoxaparin v prevenci a terapii tromboembolické nemoci u onkologických pacientů +12019 | First Faculty of Medicine
- Postavení enoxaparinu ve spektru současných antikoagulancií2019 | First Faculty of Medicine, Third Faculty of Medicine
- Commentary on a study Enoxaparin administered once a day in the treatment of outpatients with acute venous thromboembolism2011 | First Faculty of Medicine
- Účinnost a bezpečnost bemiparinu ve srovnání s enoxaparinem v prevenci pooperačního žilního tromboembolismu2019 | Third Faculty of Medicine
- Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report2023 | Second Faculty of Medicine
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty2008 | Faculty of Medicine in Pilsen
- Comparison of fondaparinux and enoxaparin in acute coronary syndromes2006 | First Faculty of Medicine, Third Faculty of Medicine
- Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study2022 | Faculty of Medicine in Hradec Králové
- Sledování aktivity anti Xa po enoxaparinu a fondaparinuxuPublication without faculty affiliation
- The purple toe syndrome in female with factor v Leiden mutation successfully treated with enoxaparin2013 | Faculty of Medicine in Hradec Králové
- Acute mesenteric ischemia as a fatal complication of infectious disease in a high-risk patient: a case report2019 | Faculty of Medicine in Pilsen
- Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery A Randomized Controlled Trial2014 | Publication without faculty affiliation
- Changes of coagulation after single i. v. bolus 0, 75 mg per kg of low molecular weight heparin enoxaparin during PCI A pharmacokinetic studyPublication without faculty affiliation
- Changes of coagulation after single i. v. bolus 0, 75 mg per kg of low molecular weight heparin enoxaparin during PCI - A pharmacokinetic studyPublication without faculty affiliation
- Changes of coagulation after single i. v. bolus 0, 75 mg per kg of low molecular weight heparin enoxaparine during PCI - a pharmacokinetic studyPublication without faculty affiliation
- Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty2008 | Faculty of Medicine in Pilsen
- Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)2010 | Third Faculty of Medicine
- Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE2012 | Second Faculty of Medicine
- Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines: Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial2009 | Third Faculty of Medicine
- Thromboembolic complications of sepsis: What is the incidence and pathophysiological mechanisms involved?2008 | First Faculty of Medicine
- Low molecular weight heparins - their significance in current practice2011 | Central Library of Charles University, Third Faculty of Medicine